Johnson & Johnson has sparked a national debate. World’s largest maker of Health care products has struck a deal to license an experimental AIDS drugs before regulatory approval.

Mitchell Warren, executive director of the New York-based AIDS Vaccine Advocacy Coalition reportedly asserted that this remarkable step could facilitate such products in the developing nations at an affordable price in comparison to that provided by the makers themselves.

Meanwhile, US pharmaceutical giant Mylan has signed an agreement with the Ireland-based Tibotec Pharmaceuticals to produce and market a generic version of the latter’s anti HIV drug Rilpivirine Hydrochloride.

Mylan president Heather Bresch reportedly claimed this remarkable step towards expanding the existing market into the developing nations to ensure suffient stock anti HIV drug Rilpivirine Hydrochloride

As per the terms of deal, Matrix would e allowed to produce fixed-dose combination product that contain multiple medicines formulated into one tablet, helping to simplify HIV therapy, which is being preferred by public health treatment programmes.

As the toll of HIV causality about to cross 1.8million, Joint United Nations Programme has declared HIV/AIDS as the world’s deadliest infection. With the recent path breaking step taken by J&J, the world’s largest maker of health
-care products, the world can expect many similar deals to be signed by rival drug makers.